ACON: Aclarion Inc Price to Sales

Symbol and logo of brand Aclarion Inc (ACON)

Risks of slow software adoption by surgeons and liquidity shortages are constraining the growth of Aclarion (ACON), as clearly demonstrated by the company's flattened P/S ratio. The current level of this metric is 46.20. Meanwhile, AI solutions for MRI scan analysis are providing a technological breakthrough in pain diagnostics. Stable demand for spinal treatment makes the business resilient to economic crises.

ACON (Aclarion, Inc.) P/S Multiple history from 04/28/2023 to 11/13/2026

Analytical breakdowns for Aclarion Corp (ACON)

- market price and analyst price targets:
Stock Quotes aclarion.com|ACON - Analyst Consensus Forecast
- market capitalization information:
Market Value Aclarion Corp|ACON - Enterprise Value
- shareholders' equity book value data:
Equity per Share Aclarion|ACON - Book Capitalization|Market Capitalization to Book Value aclarion.com|ACON - Company Total Assets
- debt obligations and liquidity statistics:
Total Debt to Equity Ratio Aclarion|ACON - Long-Term Debt to Capital|Short-Term Debt to Capital Aclarion Corporation|ACON - Company Debts|Debt to Book Capitalization Ratio Aclarion Corp|ACON - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Aclarion|Immediate Liquidity aclarion.com
- net income and valuation multiples indicators:
ACON - Company Net Income|Projected Net Profit Aclarion|ACON - Price to Earnings Ratio|Forward P/E Multiple Aclarion Inc|ACON - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Aclarion Corp|ACON - Profit before payment of interest, taxes and amortization|Earnings per one share for the last 12 months Aclarion|ACON - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months aclarion.com|ACON - Earnings growth in current year|Expected net earnings per share growth next year Aclarion
- issuer revenue and sales details:
ACON - Company Revenue|Company Revenue Forecast aclarion.com|ACON - Market Cap to Revenue|Price to Expected Revenue Ratio Aclarion Corp
Fundamental company analysis:aclarion.com ACON
Original product of Aclarion Corp

The P/S multiple determines the market value of a business relative to its generated sales volume, helping investors assess whether an asset is overpriced or if there is a "value trap" risk when quotes are excessively undervalued. By analyzing the price-to-sales trend, one can correlate market expectations with the efficiency of the cloud distribution of the Aclarion (ACON) biomarker platform, which minimizes operating expenses by eliminating physical logistics.

Who Aclarion competes with

Market Cap to Revenue abbott.com ABT|P/S Multiple TMO (Thermo Fisher)|GE HealthCare Technologies Inc. (GEHC) - Price to Sales|Mettler-Toledo International Inc. - P/S Multiple|WAT (Waters Technologies) - Market Cap to Revenue Ratio|TECH: P/S Multiple|BRKR - Price-to-Revenue Coefficient|AZTA (Azenta) - P/S Multiple|Market Cap to Revenue Varex Imaging Corp (VREX)|P/S Multiple SMLR|P/S Multiple Butterfly Corp (BFLY)|Price-to-Revenue Ratio Mesa Laboratories, Inc. MLAB|quantum-si.com - Price-to-Revenue Ratio|NNOX: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio QTRX (Quanterix Corp.)|MASS: P/S Multiple|Price to Sales CapsoVision (CV)|Price-to-Revenue Ratio MaxCyte, Inc.|RPID - Price-to-Revenue Multiple|Market Cap to Revenue SEER (Seer)|P/S Multiple Hyperfine Inc (HYPR)|P/S Multiple FONR (FONAR Corp)|Price-to-Revenue Coefficient Daxor Corp (DXR)|MDAI - Price-to-Revenue Ratio|Price-to-Sales Ratio VIVS|akoyabio.com (AKYA) - Price-to-Revenue Ratio|Market Cap to Revenue ThermoGenesis Holdings, Inc.|TLIS (Talis Biomedical Corp.) - P/S Multiple|Price to Sales T2 Biosystems Inc TTOO